Gilead supersizes remdesivir trials, changes primary endpoint

Gilead supersizes remdesivir trials, changes primary endpoint

Source: 
Fierce Biotech
snippet: 

Gilead Sciences has made major mid-study changes to its global remdesivir trials, quadrupling the enrollment target and switching the primary endpoint. The changes come as the world waits for results from the Chinese clinical trials of the advanced COVID-19 antiviral candidate.